Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone dexborneol for acute cerebral ischemia-reperfusion injury (miR-223-3p/NLRP3 pathway)
ChiCTR2300073266Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of edaravone dexborneol in ischemic stroke (2 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoint: Modified Rankin Scale score at 90 days. Started Jul 2023; status: recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300073266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073266.